ExodusPoint Capital Management’s Immunome IMNM Stock Holding History

ExodusPoint Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-115,370	Closed	-$2.52M	–	1801
2026 Q1	$2.52M	Sell	115,370 -664,208	-85%	-$14.8M	0.02%	683
2025 Q4	$16.7M	Buy	+779,578	New	+$13.7M	0.13%	132
2025 Q3	–	Sell	-81,873	Closed	-$761K	–	1761
2025 Q2	$761K	Sell	81,873 -20,280	-20%	-$166K	0.01%	1042
2025 Q1	$687K	Buy	+102,153	New	+$980K	0.01%	1024
2024 Q2	–	Sell	-34,991	Closed	-$864K	–	1726
2024 Q1	$864K	Buy	34,991 +1,849	+6%	+$37.5K	0.01%	994
2023 Q4	$355K	Buy	+33,142	New	+$276K	﹤0.01%	1128
2021 Q3	–	Sell	-12,800	Closed	-$221K	–	2360
2021 Q2	$221K	Buy	+12,800	New	+$283K	﹤0.01%	1918

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

ExodusPoint Capital Management's IMNM Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Immunome (IMNM) in Q2 2026, closing a stake of 115,370 shares — an estimated $2.52M sold.

ExodusPoint Capital Management first reported a position in IMNM in Q2 2021 and held it in 7 quarters. The position peaked at $16.7M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

ExodusPoint Capital Management reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 115,370 Immunome shares in Q2 2026, an estimated $2.52M.
ExodusPoint Capital Management first reported a position in Immunome in Q2 2021 and held it in 7 quarters.
ExodusPoint Capital Management's Immunome position peaked at $16.7M in Q4 2025.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.